Developer docs
API playgroundTry for free, no card

Search company profiles

Model Medicines

Full company profile

uuid0000asu

Namestring
Model Medicines
Legal namestring
Model Medicines, Inc.
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Model Medicines is a preclinical AI-first biotechnology company founded in 2019 and headquartered in La Jolla, California. The company develops its proprietary GALILEO AI Drug Discovery Platform, an end-to-end engine that combines target identification, ultra-large virtual screening (ULVS) at hundred-billion-compound scale, generative chemistry via the ChemPrint molecular geometric convolutional neural network, and predictive ADMET modeling through AmesNet for small molecule therapeutic discovery. The platform runs on Google Cloud infrastructure using lightweight CPU inference and has executed a record 325-billion-molecule virtual screen in 24 hours while generating over 52 trillion chemical entities.

The company operates a platform-plus-programs model anchored by two lead preclinical candidates: MDL-001, a first-in-class oral broad-spectrum antiviral targeting the conserved RdRp Thumb-1 allosteric pocket with activity demonstrated across six viral families (Orthomyxoviridae, Pneumoviridae, Coronaviridae, Flaviviridae, Kolmioviridae, and Hepadnaviridae, including influenza, RSV, SARS-CoV-2, HCV, HBV, and HDV), with IND submission targeted for late 2026; and MDL-4102, a first-in-class selective BRD4 inhibitor designed to overcome the dose-limiting thrombocytopenia that has halted prior pan-BET programs, with IND submission targeted for 2027. Scientific validation is provided by collaborations with Icahn School of Medicine at Mount Sinai (Dr. Adolfo García-Sastre, Dr. Kris White), UC San Diego (Dr. Davey Smith), and Scripps Research (Dr. Philippe Gallay).

The business model is pre-commercial. Model Medicines is pursuing licensing and co-development partnerships with pharmaceutical companies, with future revenue expected from upfront payments, development milestones, and royalties. The company is also positioning MDL-001 for U.S. government pandemic preparedness procurement via BARDA channels. To date, the company has raised approximately $22.1 million across funding rounds in 2021, 2024, and 2025, holds 15 patent families with protection through at least 2046, and operates with a lean team of 1-10 employees.

Short descriptiontext

Model Medicines is a preclinical AI-first biotechnology company that uses its proprietary GALILEO platform to discover first-in-class small molecule therapeutics, advancing MDL-001 (a broad-spectrum antiviral targeting RdRp Thumb-1 across six viral families) and MDL-4102 (a selective BRD4 inhibitor) toward pharmaceutical licensing and government procurement partnerships.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLa Jolla, United States
HQ citystring
La Jolla
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, small molecule therapeutics, broad-spectrum antivirals, preclinical drug development, biotechnology research
Industry4 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAJAE
Cheminformatics & Molecular Modeling / CADD
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIALAB
Lead Optimization & Preclinical Candidate Selection
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Pharmaceutical Preparations2834
Product category
AI Drug Discovery
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and Co-development Agreements
TypeLicensing Royalties
Description

Pre-revenue biotech seeking to license or co-develop preclinical assets including MDL-001 and MDL-4102 with pharmaceutical partners. Revenue would come from upfront payments, milestone payments, and royalties from partner development and commercialization.

modelmedicines.com
2Pandemic Preparedness Contracts
TypeLicensing Royalties
Description

Positioning MDL-001 as a tool for U.S. pandemic preparedness against future outbreak threats, potentially engaging government procurement and stockpiling arrangements.

modelmedicines.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1GALILEO
Description

AI Drug Discovery Platform that generates biochemical data points from 3D protein structures, scaling to over 500 million constellation data points

modelmedicines.com
+3 more records
Core offering1 text field

Model Medicines is an AI-first biotechnology company that uses its proprietary GALILEO AI Drug Discovery Platform to discover and develop first-in-class small molecule therapeutics targeting conserved biological choke points. The company is advancing two lead preclinical assets: MDL-001, an oral broad-spectrum antiviral targeting the RdRp Thumb-1 allosteric site across six viral families (respiratory and hepatic viruses), and MDL-4102, a selective BRD4 inhibitor for oncology, fibrosis, and cardiovascular disease. Revenue is generated through licensing and co-development partnerships with pharmaceutical companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 100% experimental hit rate identifying 12 novel broad-spectrum antiviral compounds from 52 trillion molecules explored
+4 more records
Product overview1 text field

Model Medicines is an AI-first biotechnology company operating a platform-plus-programs model. The core technology is the GALILEO™ AI Drug Discovery Platform—an end-to-end engine combining target discovery, generative chemistry (ChemPrint), ultra-large virtual screening (ULVS), and predictive ADMET capabilities (AmesNet)—used to discover and advance first-in-class small molecule therapeutics. The company maintains two lead clinical candidates: MDL-001, a broad-spectrum antiviral targeting RdRp Thumb-1 with activity across six viral families (respiratory and hepatic viruses), and MDL-4102, a selective BRD4 inhibitor for oncology and fibrotic diseases. Additional programs include the VIROMME infectious disease spin-out. The platform has screened 325 billion molecules, generated 52+ trillion chemical entities, and discovered compounds with up to 15,000-fold specificity improvements. The company holds 15 patent families covering novel compositions of matter through at least 2046.

Product and service3 records
1MDL-001
CategorySmall Molecule Therapeutics
Description

First-in-class, oral, direct-acting, broad-spectrum antiviral targeting the RdRp Thumb-1 allosteric site of viral polymerases with nanomolar potency against six viral families. Developed for licensing or co-development with pharmaceutical partners for respiratory and hepatic viral infections.

2MDL-4102
CategorySmall Molecule Therapeutics
Description

First-in-class, highly potent, and selective BRD4 inhibitor with no measurable activity against BRD2 or BRD3, addressing dose-limiting thrombocytopenia of prior pan-BET inhibitors. Discovered through a 325-billion-molecule ultra-large virtual screen for licensing or co-development with pharmaceutical partners.

3GALILEO AI Drug Discovery Platform
CategoryAI Drug Discovery Technology
Description

End-to-end AI engine that generates biochemical data points from 3D protein structures, enabling target discovery, generative chemistry, and preclinical development for AI-first drug discovery programs.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-01-01
Description

Strategic partnership with Google Cloud infrastructure to execute the 325-billion-molecule virtual screening campaign in 2025. The GALILEO platform runs on Google Cloud using Google Kubernetes Engine, AMD EPYC CPU fleets, and Cloud Storage for molecular features and prediction results.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration on MDL-001 broad-spectrum antiviral development. Includes Dr. Adolfo García-Sastre (Preclinical Development Advisor), Dr. Kris White (Preclinical Development Advisor), and Dr. Viviana Simon as collaborators on antiviral research across multiple viral families.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Preclinical development collaboration including head-to-head 28-day in vivo study comparing MDL-001 to sofosbuvir. Dr. Philippe Gallay serves as Preclinical Advisor. Research focuses on HCV, HBV, and HDV including co-infection models.

4University of California, San Diego
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration with Dr. Davey Smith (Lead Clinical Advisor, translational research virologist) on MDL-001 broad-spectrum antiviral validation. Includes preclinical efficacy studies and clinical development planning.

modelmedicines.com
Strategic tierKeyTypeStrategic or Co-development Partner
Description

Selected to present at BARDA's Enabling Technologies Showcase at the Rapid Response Partnership Vehicle General Meeting. Positioning MDL-001 and GALILEO platform as tools for U.S. pandemic preparedness against future outbreak threats.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI-driven small molecule discovery using convolutional neural networks for structure-based virtual screening; directly comparable platform focused on hit identification through atomnet technology.

TypeDirect peer
Description

AI-driven precision medicine company using CentaurAI platform for small molecule drug discovery; comparable end-to-end AI drug discovery capabilities with active pharma partnerships.

TypeDirect peer
Description

Generative biology platform for programmable therapeutics; fellow Fierce 15 alumnus using AI/ML to accelerate novel drug design across multiple therapeutic areas.

TypeDirect peer
Description

Generative AI platform for small molecule drug discovery with end-to-end target ID through preclinical capabilities; shares the AI-first biotech positioning and Fierce 15 alumni status with Model Medicines.

TypeDirect peer
Description

AI drug discovery company combining knowledge graphs with ML to identify novel targets and drug candidates; comparable platform-plus-pipeline approach to AI-driven therapeutic development.

6Isomorphic Labs
TypeDirect peer
Description

Alphabet-backed AI drug discovery company using deep learning for novel therapeutic design; comparable in applying large-scale generative AI to small molecule discovery.

TypeBroad incumbent
Description

Established computational chemistry and molecular simulation platform with internal pipeline and software licensing business; offers comparable physics-based and ML drug discovery capabilities at greater scale.

TypeDirect peer
Description

AI-driven drug discovery platform combining high-throughput biology with machine learning; directly comparable platform-plus-pipeline model and named alongside Model Medicines in Fierce Medtech Fierce 15 alumni.

TypeDirect peer
Description

AI and robotics-driven drug discovery company combining quantum physics, cloud computing, and ML; directly comparable in applying AI to accelerate small molecule discovery at scale.

TypeDirect peer
Description

AI-driven small molecule drug discovery combining graph neural networks and generative models; directly comparable as a fellow Fierce 15 alumnus focused on first-in-class therapeutics discovery.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Model Medicines

AI Drug Discoverymodelmedicines.com

Model Medicines is a preclinical AI-first biotechnology company that uses its proprietary GALILEO platform to discover first-in-class small molecule therapeutics, advancing MDL-001 (a broad-spectrum antiviral targeting RdRp Thumb-1 across six viral families) and MDL-4102 (a selective BRD4 inhibitor) toward pharmaceutical licensing and government procurement partnerships.

What Model Medicines does

Model Medicines is a preclinical AI-first biotechnology company founded in 2019 and headquartered in La Jolla, California. The company develops its proprietary GALILEO AI Drug Discovery Platform, an end-to-end engine that combines target identification, ultra-large virtual screening (ULVS) at hundred-billion-compound scale, generative chemistry via the ChemPrint molecular geometric convolutional neural network, and predictive ADMET modeling through AmesNet for small molecule therapeutic discovery. The platform runs on Google Cloud infrastructure using lightweight CPU inference and has executed a record 325-billion-molecule virtual screen in 24 hours while generating over 52 trillion chemical entities.

The company operates a platform-plus-programs model anchored by two lead preclinical candidates: MDL-001, a first-in-class oral broad-spectrum antiviral targeting the conserved RdRp Thumb-1 allosteric pocket with activity demonstrated across six viral families (Orthomyxoviridae, Pneumoviridae, Coronaviridae, Flaviviridae, Kolmioviridae, and Hepadnaviridae, including influenza, RSV, SARS-CoV-2, HCV, HBV, and HDV), with IND submission targeted for late 2026; and MDL-4102, a first-in-class selective BRD4 inhibitor designed to overcome the dose-limiting thrombocytopenia that has halted prior pan-BET programs, with IND submission targeted for 2027. Scientific validation is provided by collaborations with Icahn School of Medicine at Mount Sinai (Dr. Adolfo García-Sastre, Dr. Kris White), UC San Diego (Dr. Davey Smith), and Scripps Research (Dr. Philippe Gallay).

The business model is pre-commercial. Model Medicines is pursuing licensing and co-development partnerships with pharmaceutical companies, with future revenue expected from upfront payments, development milestones, and royalties. The company is also positioning MDL-001 for U.S. government pandemic preparedness procurement via BARDA channels. To date, the company has raised approximately $22.1 million across funding rounds in 2021, 2024, and 2025, holds 15 patent families with protection through at least 2046, and operates with a lean team of 1-10 employees.

Model Medicines firmographics

Firmographics
Name
Model Medicines
Legal name
Model Medicines, Inc.
Website
https://modelmedicines.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Model Medicines is a preclinical AI-first biotechnology company that uses its proprietary GALILEO platform to discover first-in-class small molecule therapeutics, advancing MDL-001 (a broad-spectrum antiviral targeting RdRp Thumb-1 across six viral families) and MDL-4102 (a selective BRD4 inhibitor) toward pharmaceutical licensing and government procurement partnerships.
Ownership category
akta.pro rank

Model Medicines industry classification

Industry
Product category
AI Drug Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAJAE
Cheminformatics & Molecular Modeling / CADD
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIALAB
Lead Optimization & Preclinical Candidate Selection
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • AI drug discovery
  • Small molecule therapeutics
  • Broad-spectrum antivirals
  • Preclinical drug development
  • Biotechnology research

Where Model Medicines is headquartered

Location

Headquarters

HQ city
La Jolla
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Model Medicines business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. Licensing and Co-development Agreements: Pre-revenue biotech seeking to license or co-develop preclinical assets including MDL-001 and MDL-4102 with pharmaceutical partners. Revenue would come from upfront payments, milestone payments, and royalties from partner development and commercialization.
  2. Pandemic Preparedness Contracts: Positioning MDL-001 as a tool for U.S. pandemic preparedness against future outbreak threats, potentially engaging government procurement and stockpiling arrangements.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Model Medicines product offering

Product offering

Core offering

Model Medicines is an AI-first biotechnology company that uses its proprietary GALILEO AI Drug Discovery Platform to discover and develop first-in-class small molecule therapeutics targeting conserved biological choke points. The company is advancing two lead preclinical assets: MDL-001, an oral broad-spectrum antiviral targeting the RdRp Thumb-1 allosteric site across six viral families (respiratory and hepatic viruses), and MDL-4102, a selective BRD4 inhibitor for oncology, fibrosis, and cardiovascular disease. Revenue is generated through licensing and co-development partnerships with pharmaceutical companies.

Product overview

Model Medicines is an AI-first biotechnology company operating a platform-plus-programs model. The core technology is the GALILEO™ AI Drug Discovery Platform—an end-to-end engine combining target discovery, generative chemistry (ChemPrint), ultra-large virtual screening (ULVS), and predictive ADMET capabilities (AmesNet)—used to discover and advance first-in-class small molecule therapeutics. The company maintains two lead clinical candidates: MDL-001, a broad-spectrum antiviral targeting RdRp Thumb-1 with activity across six viral families (respiratory and hepatic viruses), and MDL-4102, a selective BRD4 inhibitor for oncology and fibrotic diseases. Additional programs include the VIROMME infectious disease spin-out. The platform has screened 325 billion molecules, generated 52+ trillion chemical entities, and discovered compounds with up to 15,000-fold specificity improvements. The company holds 15 patent families covering novel compositions of matter through at least 2046.

Differentiator

Problem solved

Functional benefit

Brands

  • GALILEO: AI Drug Discovery Platform that generates biochemical data points from 3D protein structures, scaling to over 500 million constellation data points
  • ChemPrint
  • AmesNet
  • ViroMME

Products and services

  • MDL-001 First-in-class, oral, direct-acting, broad-spectrum antiviral targeting the RdRp Thumb-1 allosteric site of viral polymerases with nanomolar potency against six viral families. Developed for licensing or co-development with pharmaceutical partners for respiratory and hepatic viral infections.
  • MDL-4102 First-in-class, highly potent, and selective BRD4 inhibitor with no measurable activity against BRD2 or BRD3, addressing dose-limiting thrombocytopenia of prior pan-BET inhibitors. Discovered through a 325-billion-molecule ultra-large virtual screen for licensing or co-development with pharmaceutical partners.
  • GALILEO AI Drug Discovery Platform End-to-end AI engine that generates biochemical data points from 3D protein structures, enabling target discovery, generative chemistry, and preclinical development for AI-first drug discovery programs.

Quantifiable outcome

  • 100% experimental hit rate identifying 12 novel broad-spectrum antiviral compounds from 52 trillion molecules explored
  • +4 more outcomes

Companies that use Model Medicines

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles2 records

Model Medicines technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature4 records

Model Medicines partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and key.

  • Google CloudcoreTechnology or Integration · 1 January 2025Strategic partnership with Google Cloud infrastructure to execute the 325-billion-molecule virtual screening campaign in 2025. The GALILEO platform runs on Google Cloud using Google Kubernetes Engine, AMD EPYC CPU fleets, and Cloud Storage for molecular features and prediction results.
  • Icahn School of Medicine at Mount SinaicoreStrategic or Co-development PartnerResearch collaboration on MDL-001 broad-spectrum antiviral development. Includes Dr. Adolfo García-Sastre (Preclinical Development Advisor), Dr. Kris White (Preclinical Development Advisor), and Dr. Viviana Simon as collaborators on antiviral research across multiple viral families.
  • Scripps ResearchcoreStrategic or Co-development PartnerPreclinical development collaboration including head-to-head 28-day in vivo study comparing MDL-001 to sofosbuvir. Dr. Philippe Gallay serves as Preclinical Advisor. Research focuses on HCV, HBV, and HDV including co-infection models.
  • University of California, San DiegocoreStrategic or Co-development PartnerResearch collaboration with Dr. Davey Smith (Lead Clinical Advisor, translational research virologist) on MDL-001 broad-spectrum antiviral validation. Includes preclinical efficacy studies and clinical development planning.
  • BARDA / Rapid Response Partnership VehiclekeyStrategic or Co-development PartnerSelected to present at BARDA's Enabling Technologies Showcase at the Rapid Response Partnership Vehicle General Meeting. Positioning MDL-001 and GALILEO platform as tools for U.S. pandemic preparedness against future outbreak threats.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Model Medicines competitors and assessment

Company assessment

Direct peers

  • Atomwise: AI-driven small molecule discovery using convolutional neural networks for structure-based virtual screening; directly comparable platform focused on hit identification through atomnet technology.
  • Exscientia: AI-driven precision medicine company using CentaurAI platform for small molecule drug discovery; comparable end-to-end AI drug discovery capabilities with active pharma partnerships.
  • Generate Biomedicines: Generative biology platform for programmable therapeutics; fellow Fierce 15 alumnus using AI/ML to accelerate novel drug design across multiple therapeutic areas.
  • Insilico Medicine: Generative AI platform for small molecule drug discovery with end-to-end target ID through preclinical capabilities; shares the AI-first biotech positioning and Fierce 15 alumni status with Model Medicines.
  • BenevolentAI: AI drug discovery company combining knowledge graphs with ML to identify novel targets and drug candidates; comparable platform-plus-pipeline approach to AI-driven therapeutic development.
  • Isomorphic Labs: Alphabet-backed AI drug discovery company using deep learning for novel therapeutic design; comparable in applying large-scale generative AI to small molecule discovery.
  • Recursion Pharmaceuticals: AI-driven drug discovery platform combining high-throughput biology with machine learning; directly comparable platform-plus-pipeline model and named alongside Model Medicines in Fierce Medtech Fierce 15 alumni.
  • XtalPi: AI and robotics-driven drug discovery company combining quantum physics, cloud computing, and ML; directly comparable in applying AI to accelerate small molecule discovery at scale.
  • Genesis Therapeutics: AI-driven small molecule drug discovery combining graph neural networks and generative models; directly comparable as a fellow Fierce 15 alumnus focused on first-in-class therapeutics discovery.

Broad incumbents

  • Schrödinger, Inc. Established computational chemistry and molecular simulation platform with internal pipeline and software licensing business; offers comparable physics-based and ML drug discovery capabilities at greater scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Model Medicines social profiles

Digital presence

Model Medicines financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Model Medicines leadership team

Management profile

Number of profiles

Profiles5 records

Model Medicines funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Model Medicines M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Model Medicines

What does Model Medicines do?

Model Medicines is an AI-first biotechnology company that uses its proprietary GALILEO AI Drug Discovery Platform to discover and develop first-in-class small molecule therapeutics targeting conserved biological choke points. The company is advancing two lead preclinical assets: MDL-001, an oral broad-spectrum antiviral targeting the RdRp Thumb-1 allosteric site across six viral families (respiratory and hepatic viruses), and MDL-4102, a selective BRD4 inhibitor for oncology, fibrosis, and cardiovascular disease. Revenue is generated through licensing and co-development partnerships with pharmaceutical companies.

Is Model Medicines a public or private company?

Model Medicines is a private company. It is classified as venture growth investor backed and is currently operating.

When was Model Medicines founded?

Model Medicines was founded in 2019. It employs 11 to 50 people.

Where is Model Medicines based?

Model Medicines is headquartered in La Jolla, United States, in the North America region.

How does Model Medicines make money?

Two revenue lines are on record. Licensing and Co-development Agreements are the primary driver. The others are pandemic Preparedness Contracts.

Who are Model Medicines's main competitors?

Direct peers on record are Atomwise, Exscientia, Generate Biomedicines, Insilico Medicine, BenevolentAI, Isomorphic Labs, Recursion Pharmaceuticals, XtalPi and Genesis Therapeutics. Schrödinger, Inc. is listed as a broad incumbent.

Does Model Medicines have an API?

No public API is recorded for Model Medicines.

What industry is Model Medicines in?

Model Medicines's product category is AI Drug Discovery. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceModel Medicines to Present New Data on MDL-001 at ASV 2026: Broad-Spectrum Antiviral Activity Across Six Viral FamiliesModel Medicines will present preclinical data on MDL-001 at ASV 2026, showing broad-spectrum antiviral activity across six viral families. The oral Thumb-1 polymerase inhibitor targets both influenza-like illness and chronic hepatitis, with plans to file an FDA IND in 2027.BioSpaceAmerican Chemical Society CRT | Model Medicines Publishes Class-Leading, Regulatory Grade Toxicology Model AmesNet™, Validation of GALILEO™ Platform & ChemPrint™ Model Underpinning Drug PipelineModel Medicines published AmesNet, a deep learning model for predicting Ames test mutagenicity, in the American Chemical Society journal Chemical Research in Toxicology. The model outperformed FDA, MIT, Tencent, and University of Sydney agents, recovering 106 more true positives than DeepAmes. It enables early-stage Ames screening, shifting safety assessment from late-stage to continuous compound prioritization.BioSpaceModel Medicines to Present Data on Two First-in-Class Programs Ahead of Catalyst Regulatory Filings at the 2026 BIO International Convention in San DiegoModel Medicines will present its two lead assets, MDL-001 and MDL-4102, at the 2026 BIO International Convention in San Diego. MDL-001 targets a conserved viral polymerase pocket for broad-spectrum antiviral activity, with an IND submission targeted for late 2026. MDL-4102 is a BRD4 inhibitor for oncology and fibrosis, with an IND submission targeted for 2027.FierceBiotechWhy Model Medicines needs to ‘discover new colors’ in its AI drug discovery questModel Medicines, a La Jolla, California-based AI drug discovery company founded by Daniel Haders in 2019, has developed a unique approach combining multidisciplinary expertise and diverse training data to identify outlier chemistry rather than rediscovering known compounds. The company has virtually screened 325 billion molecules and is advancing two preclinical candidates: MDL-4102 targeting androgen receptor and BRD4 proteins for oncology indications, currently in IND-enabling studies with hopes to enter human trials next year, and MDL-001, a broad-spectrum antiviral targeting a conserved viral polymerase mechanism slated for clinical entry in 2025.BioSpaceModel Medicines to Present 325-Billion-Molecule Ultra-Large Virtual Screening at 7th ACE Drug Discovery Summit in San DiegoModel Medicines will present at the 7th ACE Drug Discovery Summit in San Diego, with Tyler Umansky delivering a session on ultra-large virtual screening. The company's GALILEO platform enabled a 325-billion-molecule screen in 2025, producing MDL-4102, a selective BRD4 inhibitor in IND-enabling studies. An IND submission is targeted for 2027.BioSpaceModel Medicines to Present End-to-End AI Drug Discovery Platform at Fierce Biotech Week 2026 in BostonModel Medicines will present its end-to-end AI drug discovery platform at Fierce Biotech Week 2026 in Boston, with CEO Daniel Haders on a panel. The company highlights its 325-billion-molecule virtual screen and two lead candidates, MDL-001 and MDL-4102, with IND submissions targeted for late 2026 and 2027.BioSpaceModel Medicines to Present at SERVC 2026: MDL-001, a Universal Direct-Acting Antiviral for Respiratory and Hepatic Viral InfectionsModel Medicines will present preclinical data for MDL-001 at SERVC 2026, an oral direct-acting antiviral targeting the RdRp Thumb-1 pocket. The compound shows broad-spectrum activity against influenza, RSV, SARS-CoV-2, and hepatitis viruses, with oral proof-of-concept in mice. The company plans to file an IND application in late 2026 and commence clinical trials in 2027.ModelmedicinesModel Medicines Unveils Groundbreaking AI Drug Discovery Advances in New Chemistry and New Biology with Two New Preprint PapersModel Medicines announced the publication of two preprint papers on bioRxiv detailing advances in AI-driven drug discovery, including the identification of RdRp Thumb-1 as a novel broad-spectrum antiviral target and MDL-001 as a potent orally bioavailable inhibitor, as well as the ChemPrint AI platform achieving a 45.5% in vitro hit rate against previously "undruggable" oncology targets AXL and BRD4. The discoveries build on the company's recent 66.7% hit rate in identifying pan-antiviral chemical entities, which the company describes as a quantum leap in leveraging AI for transformative drug development. The company indicated plans to advance MDL-001 as a broad-spectrum oral antiviral and to publish findings in peer-reviewed journals.ModelmedicinesModel Medicines Named to Fierce 15Model Medicines has been named to Fierce Medtech's 2025 "Fierce 15" list, recognizing the most groundbreaking private companies in healthcare and AI-driven drug development. The company's GALILEO™ AI platform evaluated 53 trillion virtual compounds, synthesized 12 candidates, and achieved a 100% hit rate in antiviral screening, with their AmesNet tool also outperforming traditional QSAR models in safety prediction. Model Medicines is seeking strategic partners to license or co-develop preclinical assets, including their lead candidate MDL-001 targeting viral polymerase.ModelmedicinesModel Medicines to Highlight Two IND-Track Assets, Record-Setting AI Platform at BIO Investment & Growth Summit 2026Model Medicines, an AI-first biotechnology company, announced that its Founder and CEO will present at the BIO Investment & Growth Summit 2026 in Miami Beach, Florida, showcasing two lead drug candidates advancing toward IND submission. The company will highlight its record-setting Ultra-Large Virtual Screening platform, which has executed a 325-billion-compound screen—the largest publicly reported ML-driven bioactivity screen—and preview plans for a one-trillion-compound screen. The two assets include MDL-001, a broad-spectrum antiviral targeting RdRp Thumb-1 targeting respiratory and hepatic viruses with a combined market exceeding $30 billion annually, and MDL-4102, a selective BRD4 inhibitor for oncology and fibrotic diseases with a potential addressable market exceeding $60 billion annually.